Department of Population Health, University of Kansas School of Medicine, Kansas City, USA.
Department of Population Health, University of Kansas School of Medicine, Kansas City, USA; The University of Kansas Comprehensive Cancer Center, USA.
Addict Behav. 2024 Jan;148:107877. doi: 10.1016/j.addbeh.2023.107877. Epub 2023 Oct 4.
People who smoke cigarettes are more likely than people who do not to use cannabis, including blunts, a tobacco product containing nicotine and marijuana. Blunts represent a challenge for cessation trials because nicotine could make stopping cigarettes more difficult. Few studies have examined the impact of blunt use on individuals actively engaged in a cigarette quit attempt.
Blunt use was assessed at baseline, Weeks 4, 8, 12, 16, and 26 among Black adult people who smoke enrolled in a double-blind, placebo-controlled, randomized trial of varenicline (VAR, n = 300) versus placebo (PBO, n = 200) for smoking cessation. Participants were categorized as ever blunt (blunt use reported at any timepoint) versus non-blunt (no blunt use reported). The primary outcome was salivary cotinine-verified 7-day point prevalence smoking abstinence at Weeks 12 and 26. Logistic regression examined the effects of treatment and blunt use on abstinence.
75 participants (mean age 45.6 years (SD = 12.5, range: 22,80); 32 (42%) female) reported blunt use. Logistic regression analyses showed no treatment by blunt use interaction or significant main effect of blunt use on smoking abstinence at Weeks 12 or 26 (p > 0.05). After adjusting for treatment, those who used blunts had statistically similar odds of quitting at Week 12 (OR: 0.68, 95% CI: 0.31, 1.5) and Week 26 (OR: 0.84, 95% CI: 0.38, 1.87) as those who never used blunts during the study.
Blunt use had no statistically significant impact on cessation among participants in a smoking cessation clinical trial. Future trials are needed in which the target of cessation is all combustible products.
与不吸烟的人相比，吸烟的人更有可能使用包括大麻卷烟在内的大麻制品。大麻卷烟对戒烟试验构成了挑战，因为尼古丁可能使戒烟变得更加困难。很少有研究调查过使用大麻卷烟对积极尝试戒烟的个体的影响。
在一项双盲、安慰剂对照、随机临床试验中，对 300 名使用伐伦克林（VAR）戒烟的黑人成年吸烟者和 200 名使用安慰剂（PBO）戒烟的参与者在基线、第 4、8、12、16 和 26 周评估大麻卷烟使用情况。参与者分为使用大麻卷烟者（任何时间点报告使用大麻卷烟）和不使用大麻卷烟者（未报告使用大麻卷烟）。主要结局为第 12 和 26 周时唾液可替宁验证的 7 天点现患率戒烟率。Logistic 回归分析了治疗和大麻卷烟使用对戒烟的影响。
75 名参与者（平均年龄 45.6 岁（SD=12.5，范围：22，80）；32 名（42%）女性）报告使用过大麻卷烟。Logistic 回归分析显示，治疗和大麻卷烟使用之间无交互作用，也无大麻卷烟使用对第 12 或 26 周戒烟率的显著主要影响（p>0.05）。在校正治疗后，与从不使用大麻卷烟的参与者相比，使用大麻卷烟的参与者在第 12 周（OR：0.68，95%CI：0.31，1.5）和第 26 周（OR：0.84，95%CI：0.38，1.87）停止吸烟的可能性统计学上相似。
在戒烟临床试验中，大麻卷烟使用对参与者的戒烟率没有统计学上的显著影响。需要进行未来的试验，以所有可燃产品为戒烟目标。
